Organogenesis Holdings (ORGO) Capital Expenditures (2018 - 2026)

Organogenesis Holdings' Capital Expenditures history runs 9 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 13.24% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $13.7 million (up 6.21% YoY), while the FY2025 annual figure was $14.2 million, up 41.06% from the prior year.
• Capital Expenditures was $3.1 million for Q1 2026 at Organogenesis Holdings, down from $4.7 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $19.2 million in Q3 2023 to a low of -$5.7 million in Q2 2023.
• Historically, Capital Expenditures has averaged $5.0 million across 5 years, with a median of $3.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures jumped 510.78% in 2022, then slumped 151.77% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $10.7 million in 2022, then slumped by 68.81% to $3.3 million in 2023, then climbed by 1.11% to $3.4 million in 2024, then soared by 38.41% to $4.7 million in 2025, then tumbled by 32.37% to $3.1 million in 2026.
• The last three Capital Expenditures figures came in at $3.1 million (Q1 2026), $4.7 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.